The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of recombinant human endostatin in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer (NCT00912392).
Shun Lu
No relevant relationships to disclose
Lu Li
No relevant relationships to disclose
Yi Luo
No relevant relationships to disclose
Li Zhang
No relevant relationships to disclose
Zhiwei Chen
No relevant relationships to disclose
Wu Gang
No relevant relationships to disclose
Ping Chen
No relevant relationships to disclose
Cheng Huang
No relevant relationships to disclose
Shuliang Guo
No relevant relationships to disclose
Yiping Zhang
No relevant relationships to disclose
Xiangqun Song
No relevant relationships to disclose
Meijun Lv
No relevant relationships to disclose
Wei Li
No relevant relationships to disclose
Chunhong Hu
No relevant relationships to disclose
Cheng-ping Hu
No relevant relationships to disclose